Payment overview · 2025
General Payments
$3,106.38
141 reported records · 28 companies
Healthcare provider profile · identity verified
Shyamala Kumar, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · GLENDALE, AZ · NPI 1457314841
Verified facts
What the public records show
CMS Open Payments records show Shyamala Kumar, MD received $3,106.38 in general payments during 2025 across 141 reported records.
Alexion Pharmaceuticals, Inc. accounted for 13.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Briviact, Nurtec Odt, Qulipta, Vumerity.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Qulipta by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Rytary by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VUMERITY as an associated drug or biological on 16193 records involving 4044 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vumerity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PANZYGA as an associated drug or biological on 8346 records involving 3334 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Panzyga by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Xcopri by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $403.76 | 13.0% | 8 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $303.50 | 9.8% | 14 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $273.57 | 8.8% | 18 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $230.77 | 7.4% | 12 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $227.61 | 7.3% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $207.39 | 6.7% | 10 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$134.64 | 4.3% | 4 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $132.39 | 4.3% | 7 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $116.56 | 3.8% | 6 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $111.83 | 3.6% | 4 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $90.83 | 2.9% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $89.48 | 2.9% | 5 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $87.75 | 2.8% | 5 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$72.43 | 2.3% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $70.90 | 2.3% | 4 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $70.07 | 2.3% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $69.11 | 2.2% | 4 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $62.67 | 2.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $60.67 | 1.9% | 3 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $60.29 | 1.9% | 3 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $50.87 | 1.6% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $30.68 | 1.0% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $29.90 | 1.0% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $28.94 | 0.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $25.86 | 0.8% | 1 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $23.58 | 0.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.33 | 0.7% | 1 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $20.00 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,931.38 | 140 |
| Consulting Fee | $175.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $403.76 | 8 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $207.39 | 10 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $173.41 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $172.43 | 12 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $166.82 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $141.81 | 8 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $132.39 | 7 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $131.48 | 5 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $118.52 | 11 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $116.56 | 6 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $112.25 | 1 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $111.83 | 4 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $90.83 | 4 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $82.67 | 8 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $72.43 | 3 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $70.07 | 4 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $69.11 | 4 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $67.44 | 4 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $62.67 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $62.38 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $60.67 | 3 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $60.29 | 3 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $53.26 | 3 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $52.96 | 3 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $50.95 | 3 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $50.87 | 2 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $49.09 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $41.72 | 2 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $34.49 | 2 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $34.40 | 2 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $29.18 | 2 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $27.85 | 1 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $25.78 | 1 | 2025 |
Source payment records
|
|||||
| Bafiertam Normalized: bafiertam |
Drug | Cycle Pharmaceuticals Inc | $23.58 | 1 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $23.58 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $20.33 | 1 | 2025 |
Source payment records
|
|||||
| ZEMBRACE SYMTOUCH Normalized: zembrace symtouch |
Drug | Tonix Medicines, Inc. | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $14.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 32 | exact normalized | Medicare Part D |
| Briviact briviact |
2025 | Briviact | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VUMERITY vumerity |
2025 | Vumerity | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
32 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | VUMERITY open payments reported associated product |
CMS Open Payments — General Payments 16193 supporting records · 4044 recipient NPIs · example record 1208299697 |
Vumerity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PANZYGA open payments reported associated product |
CMS Open Payments — General Payments 8346 supporting records · 3334 recipient NPIs · example record 1228795271 |
Panzyga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 306 | 111 |
| Levetiracetam | Levetiracetam | 299 | 82 |
| Donepezil Hcl | Donepezil Hcl | 263 | 108 |
| Lacosamide | Lacosamide | 235 | 48 |
| Memantine Hcl | Memantine Hcl | 188 | 73 |
| Divalproex Sodium | Divalproex Sodium | 169 | 55 |
| Lamotrigine | Lamotrigine | 166 | 29 |
| Primidone | Primidone | 154 | 29 |
| Zonisamide | Zonisamide | 139 | 32 |
| Pregabalin | Pregabalin | 119 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 113 | 40 |
| Divalproex Sodium Er | Divalproex Sodium | 93 | 24 |
| Topiramate | Topiramate | 86 | 28 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 81 | 22 |
| Clonazepam | Clonazepam | 78 | 17 |
| Oxcarbazepine | Oxcarbazepine | 71 | 15 |
| Phenobarbital | Phenobarbital | 69 | 13 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 49 | 20 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 49 | 18 |
| Carbamazepine Er | Carbamazepine | 47 | 12 |
| Baclofen | Baclofen | 44 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 44 | 15 |
| Clobazam | Clobazam | 43 | suppressed |
| Carbamazepine | Carbamazepine | 36 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 36 | 12 |
| Sertraline Hcl | Sertraline Hcl | 36 | suppressed |
| Briviact | Brivaracetam | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | 23 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 34 | 11 |
| Rytary | Carbidopa/Levodopa | 33 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 33 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 33 | suppressed |
| Botox | Onabotulinumtoxina | 32 | 12 |
| Olanzapine | Olanzapine | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 29 | 14 |
| Amantadine | Amantadine Hcl | 28 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 27 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | 14 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | 11 |
| Methocarbamol | Methocarbamol | 25 | 14 |
| Nurtec Odt | Rimegepant Sulfate | 24 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 23 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 21 | suppressed |
| Panzyga | Immun Glob G(Igg)-Ifas/Glycine | 21 | suppressed |
| Qulipta | Atogepant | 20 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 19 | suppressed |
| Tegretol Xr | Carbamazepine | 19 | suppressed |
| Xcopri | Cenobamate | 19 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 17 | suppressed |
| Lamictal | Lamotrigine | 17 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Rivastigmine | Rivastigmine | 16 | suppressed |
| Valproic Acid | Valproic Acid | 16 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 15 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Dalfampridine Er | Dalfampridine | 14 | suppressed |
| Felbamate | Felbamate | 14 | suppressed |
| Keppra | Levetiracetam | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Vumerity | Diroximel Fumarate | 14 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Fycompa | Perampanel | 11 | suppressed |
| Kesimpta Pen | Ofatumumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,106.38 · 141 records | Alexion Pharmaceuticals, Inc. | AJOVY, AUSTEDO XR, BOTOX, BRIUMVI, Bafiertam, Briviact, CREXONT, DAYBUE, EPIDIOLEX, Fintepla, INGREZZA, KESIMPTA, KISUNLA, Leqembi, Motpoly XR, NUPLAZID, NURTEC ODT, Nayzilam, Ocrevus Zunovo, QULIPTA, REXULTI, Rystiggo, TONMYA, TYSABRI, Tascenso ODT, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VUMERITY, VYALEV, VYEPTI, VYVGART, VYVGART HYTRULO, ZAVZPRET, ZEMBRACE SYMTOUCH, ZEPOSIA, Zilbrysq | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error